Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Income towards Parent Company: 2023-2025

Historic Income towards Parent Company for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's Income towards Parent Company fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 50.07%. This contributed to the annual value of -$161.3 million for FY2024, which is 334.62% down from last year.
  • As of Q3 2025, Zenas BioPharma's Income towards Parent Company stood at -$51.5 million, which was up 1.39% from -$52.2 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Income towards Parent Company registered a high of $35.6 million during Q3 2023, and its lowest value of -$56.5 million during Q4 2024.
  • For the 3-year period, Zenas BioPharma's Income towards Parent Company averaged around -$31.9 million, with its median value being -$38.0 million (2024).
  • Data for Zenas BioPharma's Income towards Parent Company shows a maximum YoY tumbled of 208.37% (in 2024) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's Income towards Parent Company (Quarterly) stood at -$24.8 million in 2023, then slumped by 128.15% to -$56.5 million in 2024, then tumbled by 33.40% to -$51.5 million in 2025.
  • Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.